Trial Information
Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters
Inclusion Criteria:
- Histologically confirmed muscle-invasive urothelial carcinoma
- Age > 18 years
- Hemoglobin > 10g/dl
- Signed Informed Consent
- Karnofsky index < 70%
Exclusion Criteria:
- Clinically relevant second malignancy
- Severe comorbidities (e.g. NYHA III, end-stage renal disease)
- Chronic infectious disease (HIV, Tuberculosis)
- Immunosupression
- Severe psychiatric diseases
- Blood donation in the last 4 weeks
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Thomas Horn, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Department of Urology, Technische Universität München
Authority:
Germany: Local ethics commission
Study ID:
IBT-1
NCT ID:
NCT01198808
Start Date:
August 2010
Completion Date:
Related Keywords:
- Bladder Cancer
- Bladder cancer
- chemotherapy
- T cells
- Immunotherapy
- Tumor-specific immunity in bladder cancer
- Urinary Bladder Neoplasms